Detection of high‐risk HPV types by the hybrid capture 2 test

A hybrid capture test that can be used to detect at least 13 high‐risk HPV types (referred to collectively as HPV‐HR) in cervical scrapes (Hybrid Capture 2 probe set B, HC2‐B) was evaluated. The HC2‐B test is accurate and highly reproducible and the results obtained show excellent agreement with those obtained by a multiplexed type‐specific polymerase chain reaction (mts‐PCR). An additional assay to identify a subset of HPV‐HR types may improve specificity without compromising sensitivity in HC2‐B positive specimens with a test result close to the cut‐off value given by 1 pg/ml HPV DNA. J. Med. Virol. 65:155–162, 2001. © 2001 Wiley‐Liss, Inc.

[1]  R. Hiatt,et al.  Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. , 1999, JAMA.

[2]  J. Cuzick,et al.  Human papillomavirus genotype as a predictor of persistence and development of high‐grade lesions in women with minor cervical abnormalities , 1996, International journal of cancer.

[3]  H. Adami,et al.  Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study , 2000, The Lancet.

[4]  C. Clavel,et al.  Human Papillomavirus Detection by the Hybrid Capture II Assay: A Reliable Test to Select Women With Normal Cervical Smears at Risk for Developing Cervical Lesions , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[5]  C. Peyton,et al.  Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. , 1994, The Journal of infectious diseases.

[6]  T. Wright,et al.  Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. , 2000, Journal of the National Cancer Institute.

[7]  R. Burk,et al.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. , 1995, Journal of the National Cancer Institute.

[8]  T. Wright,et al.  Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. , 1998, American journal of obstetrics and gynecology.

[9]  C. Gurucharri,et al.  Low‐risk human papillomavirus types 6 and 11 associated with carcinomas of the genital and upper aero‐digestive tract , 1997 .

[10]  T. Iftner,et al.  Human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix. , 1993, Human pathology.

[11]  S Wacholder,et al.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. , 2000, JAMA.

[12]  H. Adami,et al.  Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study , 2000, The Lancet.